Top intensive care body advises against Remdesivir for Covid-19 patients


By Francesco Guarascio BRUSSELS (Reuters) - Antiviral remdesivir should not be used as a routine treatment for COVID-19 patients in critical care wards, the head of one of the world's top bodies representing intensive care doctors said, in a blow to the drug developed by U.S.

firm Gilead. Remdesivir, also known as Veklury, and steroid dexamethasone are the only drugs authorised to treat COVID-19 patients across the world. But the largest study on remdesivir's efficacy, run by the World Health Organization (WHO), showed on.....

This article is no longer available in our repository.

There could be multiple reasons for this.